OBJECTIVE: We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) in a large multinational trial. BACKGROUND: Myocytes that are subjected to mechanical stress secrete ST2, a soluble interleukin-1 receptor family member that is associated with HF after STE-ACS. METHODS: We measured ST2 with a high-sensitivity assay in all available baseline samples (N=4426) in patients enrolled in the Metabolic Efficiency With Ranolazine for Less Ischemia in the Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36), a placebo-controlled trial of ranolazine in NSTE-ACS. All events, including cardiovascular death and new or worsening HF, were adjudicated by an independent events committee. RESULTS: Patients with ST2 concentrations in the top quartile (>35 μg/L) were more likely to be older and male and have diabetes and renal dysfunction. ST2 was only weakly correlated with troponin and B-type natriuretic peptide. High ST2 was associated with increased risk for CVD/HF at 30 days (6.6% vs 1.6%, P<0.0001) and 1 year (12.2% vs 5.2%, P<0.0001). The risk associated with ST2 was significant after adjustment for clinical covariates and biomarkers (adjusted hazard ratio CVD/HF 1.90, 95% CI 1.15-3.13 at 30 days, P=0.012; 1.51, 95% CI 1.15-1.98 at 1 year, P=0.003), with a significant integrated discrimination improvement (P<0.0001). No significant interaction was found between ST2 and ranolazine (Pinteraction=0.15). CONCLUSIONS:ST2 correlates weakly with biomarkers of acute injury and hemodynamic stress but is strongly associated with the risk of HF after NSTE-ACS. This biomarker and related pathway merit further investigation as potential therapeutic targets for patients with ACS at risk for cardiac remodeling.
RCT Entities:
OBJECTIVE: We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) in a large multinational trial. BACKGROUND: Myocytes that are subjected to mechanical stress secrete ST2, a soluble interleukin-1 receptor family member that is associated with HF after STE-ACS. METHODS: We measured ST2 with a high-sensitivity assay in all available baseline samples (N=4426) in patients enrolled in the Metabolic Efficiency With Ranolazine for Less Ischemia in the Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36), a placebo-controlled trial of ranolazine in NSTE-ACS. All events, including cardiovascular death and new or worsening HF, were adjudicated by an independent events committee. RESULTS:Patients with ST2 concentrations in the top quartile (>35 μg/L) were more likely to be older and male and have diabetes and renal dysfunction. ST2 was only weakly correlated with troponin and B-type natriuretic peptide. High ST2 was associated with increased risk for CVD/HF at 30 days (6.6% vs 1.6%, P<0.0001) and 1 year (12.2% vs 5.2%, P<0.0001). The risk associated with ST2 was significant after adjustment for clinical covariates and biomarkers (adjusted hazard ratio CVD/HF 1.90, 95% CI 1.15-3.13 at 30 days, P=0.012; 1.51, 95% CI 1.15-1.98 at 1 year, P=0.003), with a significant integrated discrimination improvement (P<0.0001). No significant interaction was found between ST2 and ranolazine (Pinteraction=0.15). CONCLUSIONS:ST2 correlates weakly with biomarkers of acute injury and hemodynamic stress but is strongly associated with the risk of HF after NSTE-ACS. This biomarker and related pathway merit further investigation as potential therapeutic targets for patients with ACS at risk for cardiac remodeling.
Authors: Ellen O Weinberg; Masahisa Shimpo; Gilles W De Keulenaer; Catherine MacGillivray; Shin-ichi Tominaga; Scott D Solomon; Jean-Lucien Rouleau; Richard T Lee Journal: Circulation Date: 2002-12-03 Impact factor: 29.690
Authors: Kai M Eggers; Paul W Armstrong; Robert M Califf; Maarten L Simoons; Per Venge; Lars Wallentin; Stefan K James Journal: Am Heart J Date: 2010-05 Impact factor: 4.749
Authors: K Oshikawa; K Kuroiwa; K Tago; H Iwahana; K Yanagisawa; S Ohno; S I Tominaga; Y Sugiyama Journal: Am J Respir Crit Care Med Date: 2001-07-15 Impact factor: 21.405
Authors: Sergio Manzano-Fernández; Thomas Mueller; Domingo Pascual-Figal; Quynh A Truong; James Louis Januzzi Journal: Am J Cardiol Date: 2011-01-15 Impact factor: 2.778
Authors: Ellen O Weinberg; Masahisa Shimpo; Shelley Hurwitz; Shin-ichi Tominaga; Jean-Lucien Rouleau; Richard T Lee Journal: Circulation Date: 2003-02-11 Impact factor: 29.690
Authors: Masahisa Shimpo; David A Morrow; Ellen O Weinberg; Marc S Sabatine; Sabina A Murphy; Elliott M Antman; Richard T Lee Journal: Circulation Date: 2004-04-26 Impact factor: 29.690
Authors: Markus Brunner; Claus Krenn; Georg Roth; Bernhard Moser; Martin Dworschak; Erika Jensen-Jarolim; Andreas Spittler; Thomas Sautner; Nico Bonaros; Ernst Wolner; George Boltz-Nitulescu; Hendrik Jan Ankersmit Journal: Intensive Care Med Date: 2004-02-28 Impact factor: 17.440
Authors: S J Rotz; C E Dandoy; M D Taylor; S Jodele; J L Jefferies; A Lane; J A El-Bietar; A W Powell; S M Davies; T D Ryan Journal: Bone Marrow Transplant Date: 2017-07-17 Impact factor: 5.483
Authors: William S Jenkins; Véronique L Roger; Allan S Jaffe; Susan A Weston; Omar F AbouEzzeddine; Ruoxiang Jiang; Sheila M Manemann; Maurice Enriquez-Sarano Journal: Am J Med Date: 2017-03-23 Impact factor: 4.965
Authors: Charlotte Andersson; Sarah R Preis; Alexa Beiser; Charles DeCarli; Kai C Wollert; Thomas J Wang; James L Januzzi; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2015-07-28 Impact factor: 7.914